Compare Abbott Laboratories (ABT) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Estee Lauder Companies Inc — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Estee Lauder Companies Inc trades at $87.79 (market cap $31.54B). The key difference: Abbott Laboratories is far larger — about 6× Estee Lauder Companies Inc's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | EL | |
|---|---|---|
Market Cap | $187.95B | $31.54B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $119.61 |
52-Week Low | $82.57 | $67.23 |
Enterprise Value | $214.96B | $37.72B |
Dividend Yield | 2.32% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Estée Lauder (EL) trades at $88.35, up 3.35% with a bullish technical signal and recent earnings beats. The stock shows strong institutional interest with Bank of America increasing its stake by 950.9% in Q1 2026. Despite negative net income margins, the company maintains a robust gross margin of 74.71% and has upcoming Q2 2026 earnings expected at $0.3197 per share. Recent corporate developments include a new fragrance launch and executive appointments.
The outlook remains cautiously optimistic with a consensus price target of $91.67 offering 3.8% upside potential. Key risks include declining revenue trends and negative profitability, while opportunities lie in product innovation and digital engagement. The stock faces resistance near $90-$93 levels with support at $86.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
